Mursla reports liver-specific vesicle isolation study for blood-based molecular profiling
Published in Journals, Personalized medicine, Tools.
Publication date: October 13, 2026.
Mursla Bio announced a peer-reviewed study of its NEXPLOR approach for isolating hepatocyte-derived extracellular vesicles from human plasma. The October 13 announcement cites a Journal of Extracellular Vesicles publication building on a June 2025 preprint.
The study compared liver-cell-enriched vesicles with bulk vesicle preparations from matched plasma samples of people with hepatocellular carcinoma, cirrhosis and healthy donors. Each sample required less than 2 mL of plasma, according to the company.
Mursla reports that the enriched fraction identified 57% more proteins than bulk preparations. It also yielded 86 proteins uniquely detected or significantly increased in liver disease versus healthy donors. Protein and microRNA profiles suggested that selecting vesicles by tissue origin could reveal disease-related signals masked in mixed preparations.
Limits: molecular enrichment does not establish a screening test’s sensitivity, specificity or clinical benefit. The announcement does not supply cohort size or prospective diagnostic performance. Further validation is needed before inferring reliable early cancer detection. The findings concern liver-derived vesicles; extension to other tissues remains development work.
Sources: Mursla Bio announcement, October 13, 2026; cited study, DOI: 10.1002/jev2.70372.